Paper Details
- Home
- Paper Details
Socio-economic status and the therapeutic effectiveness of antihypertensive treatment--the design of the LEO study.
Author: BramlageP, EckertM, LichtenthalA, SchmidtA C, ScholzeJ
Original Abstract of the Article :
The risk of arterial hypertension and subsequent cardiovascular disease morbidity and mortality increases with low socio-economic status (SES). Even small differences in blood pressure, whether untreated or despite treatment, account for this substantial difference. Most of the increased risk in the...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1185/030079907x226078
データ提供:米国国立医学図書館(NLM)
Socioeconomic Status and Hypertension Treatment: Addressing Health Disparities
This study focuses on the relationship between socioeconomic status (SES) and the effectiveness of antihypertensive treatment. Hypertension, or high blood pressure, is a major risk factor for cardiovascular disease, and its prevalence and severity vary across different socioeconomic groups. The study aims to explore the impact of SES on the effectiveness of antihypertensive treatment, seeking to address health disparities.
Addressing Inequalities: Seeking Equitable Outcomes
The study acknowledges that individuals with lower SES have a higher risk of hypertension and subsequent cardiovascular disease. This disparity in health outcomes is influenced by factors such as access to healthcare, lifestyle choices, and socioeconomic stressors. The study highlights the need for effective antihypertensive treatments that can address these health disparities and ensure equitable outcomes for all patients. Think of this study as a mission to create a more just and equitable desert oasis, where everyone has access to the resources and support they need to thrive.
The LEO Study: A Pathway to Improved Outcomes
The study introduces the LEO study, which will investigate the effectiveness of the angiotensin receptor blocker (ARB) olmesartan in different socioeconomic groups. This research will provide valuable insights into the potential of olmesartan to mitigate health disparities associated with hypertension. By studying the effectiveness of this drug across socioeconomic groups, researchers hope to identify strategies for improving health outcomes for all patients, regardless of their social or economic background.
Dr. Camel's Conclusion
This study underscores the critical importance of addressing health disparities associated with hypertension. The LEO study provides a valuable platform for investigating the effectiveness of antihypertensive treatment in different socioeconomic groups, paving the way for more equitable and effective healthcare for all.
Date :
- Date Completed 2007-10-17
- Date Revised 2019-09-11
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.